Sit Investment Associates Inc. Buys New Shares in TransMedics Group, Inc. (NASDAQ:TMDX)

Sit Investment Associates Inc. acquired a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 6,780 shares of the company's stock, valued at approximately $423,000.

Several other institutional investors and hedge funds have also modified their holdings of TMDX. Quarry LP raised its stake in TransMedics Group by 557.1% during the third quarter. Quarry LP now owns 368 shares of the company's stock worth $58,000 after acquiring an additional 312 shares in the last quarter. National Bank of Canada FI grew its holdings in shares of TransMedics Group by 174.7% during the 3rd quarter. National Bank of Canada FI now owns 412 shares of the company's stock valued at $65,000 after purchasing an additional 262 shares during the last quarter. Atlas Capital Advisors Inc. acquired a new position in TransMedics Group during the 4th quarter worth approximately $31,000. Hager Investment Management Services LLC bought a new position in TransMedics Group in the 4th quarter valued at approximately $33,000. Finally, Sachetta LLC acquired a new stake in TransMedics Group in the fourth quarter valued at approximately $40,000. 99.67% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

TMDX has been the subject of several research analyst reports. Canaccord Genuity Group reiterated a "buy" rating and set a $104.00 price target on shares of TransMedics Group in a report on Tuesday, March 11th. Needham & Company LLC restated a "hold" rating on shares of TransMedics Group in a research report on Wednesday, March 26th. Finally, JPMorgan Chase & Co. reiterated a "neutral" rating and issued a $75.00 target price (down from $116.00) on shares of TransMedics Group in a research report on Tuesday, December 17th. Three investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $122.70.

Remove Ads

TransMedics Group Trading Up 5.5 %

Shares of TMDX stock traded up $4.21 on Friday, hitting $80.58. The company had a trading volume of 1,036,118 shares, compared to its average volume of 1,331,626. TransMedics Group, Inc. has a twelve month low of $55.00 and a twelve month high of $177.37. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. The firm has a market cap of $2.71 billion, a P/E ratio of 85.72 and a beta of 2.14. The stock's 50-day moving average is $70.94 and its two-hundred day moving average is $81.62.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.